Pfizer Inc. (NYSE:PFE) Shares Sold by Town & Country Bank & Trust CO dba First Bankers Trust CO

Town & Country Bank & Trust CO dba First Bankers Trust CO decreased its holdings in Pfizer Inc. (NYSE:PFE) by 3.6% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,176 shares of the biopharmaceutical company’s stock after selling 970 shares during the quarter. Town & Country Bank & Trust CO dba First Bankers Trust CO’s holdings in Pfizer were worth $694,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. AQR Capital Management LLC boosted its position in Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after acquiring an additional 9,435 shares during the last quarter. Ascent Group LLC increased its holdings in shares of Pfizer by 23.2% in the second quarter. Ascent Group LLC now owns 50,845 shares of the biopharmaceutical company’s stock valued at $1,423,000 after purchasing an additional 9,565 shares during the last quarter. Creative Planning lifted its position in Pfizer by 13.3% during the second quarter. Creative Planning now owns 1,554,564 shares of the biopharmaceutical company’s stock worth $43,497,000 after buying an additional 182,950 shares in the last quarter. Magnolia Capital Advisors LLC acquired a new position in Pfizer during the second quarter worth $409,000. Finally, Silver Lake Advisory LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $208,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on PFE shares. Citigroup assumed coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Bank of America restated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Truist Financial lowered their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Finally, Wolfe Research started coverage on shares of Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.00.

Pfizer Stock Up 2.9 %

PFE stock opened at $26.86 on Tuesday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The company has a fifty day moving average of $26.11 and a 200-day moving average of $27.94. The stock has a market capitalization of $152.19 billion, a PE ratio of 36.29, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) EPS. The firm’s quarterly revenue was up 31.2% on a year-over-year basis. As a group, analysts expect that Pfizer Inc. will post 2.94 EPS for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.40%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Insiders Place Their Bets

In related news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.